ArticleBritish journal of clinical pharmacology2021

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.

Lene Nygaard Axelsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.